{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T10:44:57Z","timestamp":1794566697409,"version":"4.9.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T00:00:00Z","timestamp":1620950400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T00:00:00Z","timestamp":1620950400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["MOST108-2314-B-182-006"],"award-info":[{"award-number":["MOST108-2314-B-182-006"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008904","name":"Ministry of Health and Welfare, Taiwan | Taipei Hospital","doi-asserted-by":"publisher","award":["MOHW109-TDU-B-212-134011"],"award-info":[{"award-number":["MOHW109-TDU-B-212-134011"]}],"id":[{"id":"10.13039\/100008904","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Blast crisis (BC) predicts dismal outcomes in patients with chronic myeloid leukaemia (CML). Although additional genetic alterations play a central role in BC, the landscape and prognostic impact of these alterations remain elusive. Here, we comprehensively investigate genetic abnormalities in 136 BC and 148 chronic phase (CP) samples obtained from 216 CML patients using exome and targeted sequencing. One or more genetic abnormalities are found in 126 (92.6%) out of the 136 BC patients, including the <jats:italic>RUNX1<\/jats:italic>-<jats:italic>ETS2<\/jats:italic> fusion and <jats:italic>NBEAL2<\/jats:italic> mutations. The number of genetic alterations increase during the transition from CP to BC, which is markedly suppressed by tyrosine kinase inhibitors (TKIs). The lineage of the BC and prior use of TKIs correlate with distinct molecular profiles. Notably, genetic alterations, rather than clinical variables, contribute to a better prediction of BC prognosis. In conclusion, genetic abnormalities can help predict clinical outcomes and can guide clinical decisions in CML.<\/jats:p>","DOI":"10.1038\/s41467-021-23097-w","type":"journal-article","created":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T10:03:17Z","timestamp":1620986597000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":83,"title":["Clonal evolution and clinical implications of genetic abnormalities in blastic transformation of chronic myeloid leukaemia"],"prefix":"10.1038","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8472-6164","authenticated-orcid":false,"given":"Yotaro","family":"Ochi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Jung","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Chung","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhito","family":"Nannya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8521-9316","authenticated-orcid":false,"given":"Ko","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9736-9469","authenticated-orcid":false,"given":"Kinuko","family":"Mitani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1418-0677","authenticated-orcid":false,"given":"Noriko","family":"Hosoya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiro","family":"Hiramoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Branford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5895-8797","authenticated-orcid":false,"given":"Naranie","family":"Shanmuganathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuma","family":"Ohyashiki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6758-3787","authenticated-orcid":false,"given":"Naoto","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoiku","family":"Takaku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun","family":"Tsuchiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiro","family":"Kanemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1682-7777","authenticated-orcid":false,"given":"Nobuhiko","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasunori","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Yoshihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rabindranath","family":"Bera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Shiozawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanying","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"June","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosaku","family":"Watatani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rurika","family":"Okuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Makishima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Shiraishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Chiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9634-8922","authenticated-orcid":false,"given":"Hiroko","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0666-1996","authenticated-orcid":false,"given":"Masashi","family":"Sanada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7678-4284","authenticated-orcid":false,"given":"Akifumi","family":"Takaori-Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Miyano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seishi","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1866-7922","authenticated-orcid":false,"given":"Lee-Yung","family":"Shih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,14]]},"reference":[{"key":"23097_CR1","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1182\/blood-2012-03-380147","volume":"120","author":"R Hehlmann","year":"2012","unstructured":"Hehlmann, R. How I treat CML blast crisis. Blood 120, 737\u2013747 (2012).","journal-title":"Blood"},{"key":"23097_CR2","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1126\/science.1062538","volume":"293","author":"ME Gorre","year":"2001","unstructured":"Gorre, M. E. et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293, 876\u2013880 (2001).","journal-title":"Science"},{"key":"23097_CR3","doi-asserted-by":"publisher","first-page":"4010","DOI":"10.1182\/blood-2003-12-4111","volume":"103","author":"B Calabretta","year":"2004","unstructured":"Calabretta, B. & Perrotti, D. The biology of CML blast crisis. Blood 103, 4010\u20134022 (2004).","journal-title":"Blood"},{"key":"23097_CR4","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1002\/gcc.20303","volume":"45","author":"N Hosoya","year":"2006","unstructured":"Hosoya, N. et al. Genomewide screening of DNA copy number changes in chronic myelogenous leukemia with the use of high-resolution array-based comparative genomic hybridization. Genes Chromosomes Cancer 45, 482\u2013494 (2006).","journal-title":"Genes Chromosomes Cancer"},{"key":"23097_CR5","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/nature06866","volume":"453","author":"CG Mullighan","year":"2008","unstructured":"Mullighan, C. G. et al. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature 453, 110\u2013114 (2008).","journal-title":"Nature"},{"key":"23097_CR6","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1182\/blood-2009-03-210377","volume":"115","author":"D Nowak","year":"2010","unstructured":"Nowak, D. et al. SNP array analysis of tyrosine kinase inhibitor-resistant chronic myeloid leukemia identifies heterogeneous secondary genomic alterations. Blood 115, 1049\u20131053 (2010).","journal-title":"Blood"},{"key":"23097_CR7","doi-asserted-by":"publisher","first-page":"e198","DOI":"10.1182\/blood-2010-06-292433","volume":"117","author":"H Makishima","year":"2011","unstructured":"Makishima, H. et al. CBL, CBLB, TET2, ASXL1, and IDH1\/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia. Blood 117, e198\u2013e206 (2011).","journal-title":"Blood"},{"key":"23097_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2013.54","volume":"3","author":"J Menezes","year":"2013","unstructured":"Menezes, J. et al. ASXL1, TP53 and IKZF3 mutations are present in the chronic phase and blast crisis of chronic myeloid leukemia. Blood Cancer J. 3, e157 (2013).","journal-title":"Blood Cancer J."},{"key":"23097_CR9","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1038\/leu.2014.272","volume":"28","author":"M Schmidt","year":"2014","unstructured":"Schmidt, M. et al. Molecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL status. Leukemia 28, 2292\u20132299 (2014).","journal-title":"Leukemia"},{"key":"23097_CR10","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1182\/blood-2016-04-708560","volume":"129","author":"T Kim","year":"2017","unstructured":"Kim, T. et al. Spectrum of somatic mutation dynamics in chronic myeloid leukemia following tyrosine kinase inhibitor therapy. Blood 129, 38\u201347 (2017).","journal-title":"Blood"},{"key":"23097_CR11","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/leu.2016.231","volume":"31","author":"Z Chen","year":"2017","unstructured":"Chen, Z. et al. Cytogenetic landscape and impact in blast phase of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Leukemia 31, 585\u2013592 (2017).","journal-title":"Leukemia"},{"key":"23097_CR12","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.leukres.2017.06.009","volume":"59","author":"T Kim","year":"2017","unstructured":"Kim, T. et al. Exome sequencing reveals DNMT3A and ASXL1 variants associate with progression of chronic myeloid leukemia after tyrosine kinase inhibitor therapy. Leuk. Res. 59, 142\u2013148 (2017).","journal-title":"Leuk. Res."},{"key":"23097_CR13","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1182\/blood-2018-02-832253","volume":"132","author":"S Branford","year":"2018","unstructured":"Branford, S. et al. Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease. Blood 132, 948\u2013961 (2018).","journal-title":"Blood"},{"key":"23097_CR14","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.3324\/haematol.2017.179937","volume":"104","author":"V Magistroni","year":"2019","unstructured":"Magistroni, V. et al. De novo UBE2A mutations are recurrently acquired during chronic myeloid leukemia progression and interfere with myeloid differentiation pathways. Haematologica 104, 1789\u20131797 (2019).","journal-title":"Haematologica"},{"key":"23097_CR15","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1182\/bloodadvances.2019000943","volume":"4","author":"S Adnan Awad","year":"2020","unstructured":"Adnan Awad, S. et al. Mutation accumulation in cancer genes relates to nonoptimal outcome in chronic myeloid leukemia. Blood Adv. 4, 546\u2013559 (2020).","journal-title":"Blood Adv."},{"key":"23097_CR16","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1182\/blood.2020004834","volume":"135","author":"TK Ko","year":"2020","unstructured":"Ko, T. K. et al. An integrative model of pathway convergence in genetically heterogeneous blast crisis chronic myeloid leukemia. Blood 135, 2337\u20132353 (2020).","journal-title":"Blood"},{"key":"23097_CR17","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1038\/s41375-019-0512-y","volume":"33","author":"S Branford","year":"2019","unstructured":"Branford, S. et al. Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia. Leukemia 33, 1835\u20131850 (2019).","journal-title":"Leukemia"},{"key":"23097_CR18","doi-asserted-by":"publisher","first-page":"4391","DOI":"10.1002\/cncr.30864","volume":"123","author":"P Jain","year":"2017","unstructured":"Jain, P. et al. Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: cohort study of 477 patients. Cancer 123, 4391\u20134402 (2017).","journal-title":"Cancer"},{"key":"23097_CR19","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1182\/blood-2016-12-754796","volume":"129","author":"T Yoshizato","year":"2017","unstructured":"Yoshizato, T. et al. Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation. Blood 129, 2347\u20132358 (2017).","journal-title":"Blood"},{"key":"23097_CR20","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1038\/ng.3415","volume":"47","author":"K Kataoka","year":"2015","unstructured":"Kataoka, K. et al. Integrated molecular analysis of adult T cell leukemia\/lymphoma. Nat. Genet. 47, 1304\u20131315 (2015).","journal-title":"Nat. Genet."},{"key":"23097_CR21","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1182\/blood-2016-06-723494","volume":"128","author":"K Mitani","year":"2016","unstructured":"Mitani, K. et al. Somatic mosaicism in chronic myeloid leukemia in remission. Blood 128, 2863\u20132866 (2016).","journal-title":"Blood"},{"key":"23097_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2017.36","volume":"7","author":"E Togasaki","year":"2017","unstructured":"Togasaki, E. et al. Frequent somatic mutations in epigenetic regulators in newly diagnosed chronic myeloid leukemia. Blood Cancer J. 7, e559 (2017).","journal-title":"Blood Cancer J."},{"key":"23097_CR23","doi-asserted-by":"publisher","first-page":"5798","DOI":"10.1002\/jcp.27505","volume":"234","author":"AA Asnafi","year":"2019","unstructured":"Asnafi, A. A., Deris Zayeri, Z., Shahrabi, S., Zibara, K. & Vosughi, T. Chronic myeloid leukemia with complex karyotypes: Prognosis and therapeutic approaches. J. Cell Physiol. 234, 5798\u20135806 (2019).","journal-title":"J. Cell Physiol."},{"key":"23097_CR24","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/leu.2010.298","volume":"25","author":"V Grossmann","year":"2011","unstructured":"Grossmann, V. et al. A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of cases. Leukemia 25, 557\u2013560 (2011).","journal-title":"Leukemia"},{"key":"23097_CR25","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1038\/s41591-020-1008-z","volume":"26","author":"E Bernard","year":"2020","unstructured":"Bernard, E. et al. Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. Nat. Med. 26, 1549\u20131556 (2020).","journal-title":"Nat. Med."},{"key":"23097_CR26","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","volume":"34","author":"A Hochhaus","year":"2020","unstructured":"Hochhaus, A. et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia 34, 966\u2013984 (2020).","journal-title":"Leukemia"},{"key":"23097_CR27","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","volume":"371","author":"S Jaiswal","year":"2014","unstructured":"Jaiswal, S. et al. Age-related clonal hematopoiesis associated with adverse outcomes. N. Engl. J. Med. 371, 2488\u20132498 (2014).","journal-title":"N. Engl. J. Med."},{"key":"23097_CR28","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1038\/s41375-018-0157-2","volume":"32","author":"T Ernst","year":"2018","unstructured":"Ernst, T. et al. Frequent ASXL1 mutations in children and young adults with chronic myeloid leukemia. Leukemia 32, 2046\u20132049 (2018).","journal-title":"Leukemia"},{"key":"23097_CR29","doi-asserted-by":"publisher","first-page":"2400","DOI":"10.3324\/haematol.2018.200220","volume":"104","author":"G Nteliopoulos","year":"2019","unstructured":"Nteliopoulos, G. et al. Somatic variants in epigenetic modifiers can predict failure of response to imatinib but not to second-generation tyrosine kinase inhibitors. Haematologica 104, 2400\u20132409 (2019).","journal-title":"Haematologica"},{"key":"23097_CR30","doi-asserted-by":"publisher","first-page":"E623","DOI":"10.1002\/ajh.24865","volume":"92","author":"L Mologni","year":"2017","unstructured":"Mologni, L., Piazza, R., Khandelwal, P., Pirola, A. & Gambacorti-Passerini, C. Somatic mutations identified at diagnosis by exome sequencing can predict response to imatinib in chronic phase chronic myeloid leukemia (CML) patients. Am. J. Hematol. 92, E623\u2013E625 (2017).","journal-title":"Am. J. Hematol."},{"key":"23097_CR31","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1056\/NEJMoa1611604","volume":"376","author":"RC Lindsley","year":"2017","unstructured":"Lindsley, R. C. et al. Prognostic mutations in myelodysplastic syndrome after stem-cell transplantation. N. Engl. J. Med. 376, 536\u2013547 (2017).","journal-title":"N. Engl. J. Med."},{"key":"23097_CR32","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1200\/JCO.2016.67.3616","volume":"34","author":"MGD Porta","year":"2016","unstructured":"Porta, M. G. D. et al. Clinical effects of driver somatic mutations on the outcomes of patients with myelodysplastic syndromes treated with allogeneic hematopoietic stem-cell transplantation. J. Clin. Oncol. 34, 3627\u20133637 (2016).","journal-title":"J. Clin. Oncol."},{"key":"23097_CR33","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","volume":"368","author":"TJ Ley","year":"2013","unstructured":"Ley, T. J. et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N. Engl. J. Med. 368, 2059\u20132074 (2013).","journal-title":"N. Engl. J. Med."},{"key":"23097_CR34","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1182\/blood.V94.1.225.413k24_225_232","volume":"94","author":"T Fioretos","year":"1999","unstructured":"Fioretos, T. et al. Isochromosome 17q in blast crisis of chronic myeloid leukemia and in other hematologic malignancies is the result of clustered breakpoints in 17p11 and is not associated with coding TP53 mutations. Blood 94, 225\u2013232 (1999).","journal-title":"Blood"},{"key":"23097_CR35","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1002\/cncr.26537","volume":"118","author":"R Kanagal-Shamanna","year":"2012","unstructured":"Kanagal-Shamanna, R. et al. Myeloid neoplasms with isolated isochromosome 17q represent a clinicopathologic entity associated with myelodysplastic\/myeloproliferative features, a high risk of leukemic transformation, and wild-type TP53. Cancer 118, 2879\u20132888 (2012).","journal-title":"Cancer"},{"key":"23097_CR36","doi-asserted-by":"publisher","first-page":"2742","DOI":"10.1182\/blood-2016-01-690230","volume":"127","author":"W Wang","year":"2016","unstructured":"Wang, W. et al. Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. Blood 127, 2742\u20132750 (2016).","journal-title":"Blood"},{"key":"23097_CR37","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/s41586-018-0623-z","volume":"562","author":"JW Tyner","year":"2018","unstructured":"Tyner, J. W. et al. Functional genomic landscape of acute myeloid leukaemia. Nature 562, 526\u2013531 (2018).","journal-title":"Nature"},{"key":"23097_CR38","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1038\/ng.883","volume":"43","author":"M Gunay-Aygun","year":"2011","unstructured":"Gunay-Aygun, M. et al. NBEAL2 is mutated in gray platelet syndrome and is required for biogenesis of platelet \u03b1-granules. Nat. Genet. 43, 732\u2013734 (2011).","journal-title":"Nat. Genet."},{"key":"23097_CR39","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1038\/ng.884","volume":"43","author":"WH Kahr","year":"2011","unstructured":"Kahr, W. H. et al. Mutations in NBEAL2, encoding a BEACH protein, cause gray platelet syndrome. Nat. Genet. 43, 738\u2013740 (2011).","journal-title":"Nat. Genet."},{"key":"23097_CR40","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1038\/ng.885","volume":"43","author":"CA Albers","year":"2011","unstructured":"Albers, C. A. et al. Exome sequencing identifies NBEAL2 as the causative gene for gray platelet syndrome. Nat. Genet. 43, 735\u2013737 (2011).","journal-title":"Nat. Genet."},{"key":"23097_CR41","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.gene.2019.03.067","volume":"702","author":"S Jia","year":"2019","unstructured":"Jia, S. et al. Identification of novel pathogenic F13A1 mutation and novel NBEAL2 gene missense mutation in a pedigree with hereditary congenital factor XIII deficiency. Gene 702, 143\u2013147 (2019).","journal-title":"Gene"},{"key":"23097_CR42","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1038\/s41375-017-0002-z","volume":"32","author":"A Stengel","year":"2018","unstructured":"Stengel, A. et al. Detection of recurrent and of novel fusion transcripts in myeloid malignancies by targeted RNA sequencing. Leukemia 32, 1229\u20131238 (2018).","journal-title":"Leukemia"},{"key":"23097_CR43","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1038\/sj.leu.2401592","volume":"13","author":"JJ van Dongen","year":"1999","unstructured":"van Dongen, J. J. et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 concerted action: investigation of minimal residual disease in acute leukemia. Leukemia 13, 1901\u20131928 (1999).","journal-title":"Leukemia"},{"key":"23097_CR44","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1038\/sj.leu.2403135","volume":"17","author":"J Gabert","year":"2003","unstructured":"Gabert, J. et al. Standardization and quality control studies of \u2018real-time\u2019 quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. Leukemia 17, 2318\u20132357 (2003).","journal-title":"Leukemia"},{"key":"23097_CR45","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.leukres.2012.09.012","volume":"37","author":"LY Shih","year":"2013","unstructured":"Shih, L. Y. et al. Emerging kinetics of BCR-ABL1 mutations and their effect on disease outcomes in chronic myeloid leukemia patients with imatinib failure. Leuk. Res. 37, 43\u201349 (2013).","journal-title":"Leuk. Res."},{"key":"23097_CR46","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/nature10496","volume":"478","author":"K Yoshida","year":"2011","unstructured":"Yoshida, K. et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 478, 64\u201369 (2011).","journal-title":"Nature"},{"key":"23097_CR47","doi-asserted-by":"publisher","first-page":"e89","DOI":"10.1093\/nar\/gkt126","volume":"41","author":"Y Shiraishi","year":"2013","unstructured":"Shiraishi, Y. et al. An empirical Bayesian framework for somatic mutation detection from cancer genome sequencing data. Nucleic Acids Res. 41, e89 (2013).","journal-title":"Nucleic Acids Res."},{"key":"23097_CR48","doi-asserted-by":"publisher","first-page":"2747","DOI":"10.1093\/bioinformatics\/bts526","volume":"28","author":"V Plagnol","year":"2012","unstructured":"Plagnol, V. et al. A robust model for read count data in exome sequencing experiments and implications for copy number variant calling. Bioinformatics 28, 2747\u20132754 (2012).","journal-title":"Bioinformatics"},{"key":"23097_CR49","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1038\/ng.3273","volume":"47","author":"H Suzuki","year":"2015","unstructured":"Suzuki, H. et al. Mutational landscape and clonal architecture in grade II and III gliomas. Nat. Genet. 47, 458\u2013468 (2015).","journal-title":"Nat. Genet."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-23097-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-23097-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-23097-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T12:24:46Z","timestamp":1669983886000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-23097-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,14]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["23097"],"URL":"https:\/\/doi.org\/10.1038\/s41467-021-23097-w","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,14]]},"assertion":[{"value":"18 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.B. is a member of the advisory boards of Qiagen, Novartis, and Cepheid and has received honoraria from Qiagen, Novartis, Bristol-Myers Squibb, and Cepheid, as well as research support from Novartis. The remaining authors declare no competing interests relevant to this study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2833"}}